Skip to main content
Caplight Logo









SHIFTBIO

SHIFTBIO

Private
SeoulHealthcare & Life Scienceshttps://shiftbio.net/

Last Round

VC Round

Feb 1, 2024

Company Overview

SHIFTBIO is a biotechnology company that develops a nanoparticle-based drug delivery system designed for targeted therapeutic applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

drug delivery platformnatural nanoparticle deliveryexosome drug deliveryAI drug discoverybiologics deliveryblood-brain barrier deliveryBBB deliveryRNA deliveryNNP deliveryprotein deliveryin silico drug designgene therapy deliveryextracellular vesiclesundruggable targetsoncology drug deliveryGMP manufacturingbiotech partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SHIFTBIO Comparables

Compare SHIFTBIO with similar companies based on industry and business-model similarity.

SHIFTBIO comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Evox Therapeutics
83%
ILIAS Biologics Inc.
81%
Exocure
79%

SHIFTBIO Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundFeb 1, 2024
AcceleratorJun 3, 2022

Key People

Founding team and executive leadership

Gi-Hoon Nam

Chief Executive Officer

Executive Team

Hyunsuk Shin

Chief Operating Officer

Executive Team

SHIFTBIO Investors

Notable investors and investment history

SHIFTBIO investors
InvestorRounds
Korea University HoldingsAccelerator
Korea Credit Guarantee FundAccelerator
Government of South KoreaAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 254% MoM.

  • Oct 29, 2024

    Monthly visitors grew 182% MoM.

SHIFTBIO Filings

Explore SEC and related filing metadata, where available.

SHIFTBIO filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SHIFTBIO's valuation, stock price, and market status.

Is SHIFTBIO a public or private company?

SHIFTBIO is a private company.

What is the current stock price of SHIFTBIO?

SHIFTBIO is a private company with no public stock price. No recent secondary market data is available.

How much is SHIFTBIO worth (valuation)?

Valuation information for SHIFTBIO is not publicly available.

Can I buy SHIFTBIO stock?

SHIFTBIO shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SHIFTBIO's last funding round?

SHIFTBIO's most recent funding round was VC Round on February 1, 2024.

Who are the main investors in SHIFTBIO?

Key investors in SHIFTBIO include Korea University Holdings, Korea Credit Guarantee Fund, Government of South Korea.

Will SHIFTBIO IPO soon?

No public IPO plans have been announced for SHIFTBIO.

How can I track SHIFTBIO secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SHIFTBIO's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range15
Year Founded2020
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?